glp-1/gip/gcg receptor agonist Dual GIP/GLP-1 agonists: New advances for treating type-2 diabetes Science Behind GLP 1 GIP

GLP-1 drugs could rapidly evolve beyond current use as diabetes and weight loss medications, with new research pointing to potential benefits in cancer, ageing, addiction, osteoarthritis and heart health

What Is A GLP-1 Agonist

Despite their exploding popularity, the current GLP-1 injections (semaglutide though is also orally available) face accessibility issues due to cost and adverse effects and thus the next big move for the space, an easy to - pop pill could be lucrative, for which clinical trials are already well underway

In this Review, the possibilities for utilizing GLP-1 receptor agonists in individualized treatment for type 2 diabetes mellitus are discussed

Amgens MariTide leads the GLP-1 obesity therapy market in 2025 with innovative design, Phase-3 trials, and strong potential for effective weight loss.

The cohort comprised patients over 20 years old who were newly treated with glucose-lowering drugs between 1 January 2013 and 31 December 2021, and followed until 30 September 2022